Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily

• Published in: Urology (Ridgewood, N.J.) Vol. 66; no. 2; pp. 316 - 322
• Main Authors: Emberton, Mark, Elhilali, Mostafa, Matzkin, Haim, Harving, Niels, van Moorselaar, Jeroen, Hartung, Rudolf, Alcaraz, Antonio, Vallancien, Guy
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.08.2005; Elsevier Science
• Subjects: Acute Disease; Adrenergic alpha-Antagonists - administration & dosage; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Drug Administration Schedule; Humans; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Prostatic Hyperplasia - complications; Prostatic Hyperplasia - drug therapy; Prostatic Hyperplasia - surgery; Quinazolines - administration & dosage; Urinary Retention - etiology; Urinary Retention - surgery; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; Urination Disorders - drug therapy; Urination Disorders - etiology; Human; Nephrology; Urinary system disease; Prognosis; Alfuzosin; Quinazoline derivatives; α1-Adrenergic receptor; Male; Urinary tract disease; History; Case history; Urology; Voiding dysfunction; Symptomatology; Daily; Alpha blocking agent; Treatment; Deterioration; Surgery; Adult; Antagonist; Predictive factor; Lower urinary tract symptoms
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/j.urology.2005.03.024

To assess the predictors of acute urinary retention (AUR) and/or surgery related to benign prostatic hyperplasia (BPH) in 3514 men complaining of lower urinary tract symptoms and treated for 6 months with the selective alpha 1-blocker alfuzosin at 10 mg once daily. The impact of baseline (age, prior AUR, prostate-specific antigen tertiles, lower urinary tract symptoms severity, and bother score) and dynamic (International Prostate Symptom Score [IPSS] worsening of 4 points or greater and bother greater than 3 during treatment) variables on the risk of AUR/BPH-related surgery was assessed using Kaplan-Meier curves and log-rank tests. Associated hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazard models. Of the 3514 men analyzed, 140 (4%) experienced a first episode of conservatively managed AUR before inclusion. Of those 140 men, 5 (3.6%) had AUR relapse during alfuzosin treatment and 6 (4.3%) underwent BPH-related surgery. Of those 3374 men without prior AUR, 19 (0.6%) experienced AUR during treatment and 41 (1.2%) underwent BPH-related surgery. During treatment, the most important predictors of AUR were prior AUR (HR 6.35, 95% CI 2.31 to 17.40; P <0.01), IPSS worsening of 4 or greater (HR 3.34, 95% CI 1.11 to 9.99; P = 0.03), and bother score greater than 3 (HR 3.32, 95% CI 1.29 to 8.53; P <0.01) at endpoint. Other variables (age, PSA, baseline IPSS, and bother) had much less predictive value. Similar results were observed regarding the risk of AUR and/or BPH-related surgery. The results of this 6-month real life practice study suggest that prior AUR and symptom deterioration during treatment with alfuzosin 10 mg once-daily (IPSS worsening of 4 or more points, bother score greater than 3) were the strongest predictors of AUR and AUR/BPH-related surgery in men with lower urinary tract symptoms.